^
    1m
    EP0031-101: A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies (clinicaltrials.gov)
    P1/2, N=265, Recruiting, Ellipses Pharma | Trial completion date: Jun 2027 --> Mar 2028 | Trial primary completion date: Dec 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion
    |
    cisplatin • carboplatin • pemetrexed • lunbotinib (EP0031)
    8ms
    A Study of KL590586 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=414, Active, not recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial completion date: May 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    lunbotinib (EP0031)
    2years
    A Study of KL590586 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=414, Active, not recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Enrolling by invitation --> Active, not recruiting
    Enrollment closed • Metastases
    |
    lunbotinib (EP0031)
    over2years
    A Study of EP0031-101 in Patients With Advanced RET-altered Malignancies (clinicaltrials.gov)
    P1/2, N=265, Recruiting, Ellipses Pharma
    Trial completion date • Trial primary completion date • Metastases
    |
    lunbotinib (EP0031)